Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zero Candida TechnologiesTSXV:ZCT 15 Equity-to-Asset is 0.41 as of Jun. 2026, which is at its 10-year median of 0.41. GuruFocus rates TSXV:ZCT with a GF Score™ of 15/100. The stock has 1 warning sign investors should review. Among 851 Medical Devices & Instruments companies, Zero Candida Technologies ranks worse than 75.44% on this metric.
The historical rank and industry rank for Zero Candida Technologies's Equity-to-Asset or its related term are showing as below:
TSXV:ZCT'
s Equity-to-Asset Range Over the Past 10 Years
Min: -6.75 Med: 0.41 Max: 0.63
Current: 0.41
During the past 3 years, the highest Equity to Asset Ratio of Zero Candida Technologies was 0.63. The lowest was -6.75. And the median was 0.41.
TSXV:ZCT's Equity-to-Asset is ranked worse than 75.44% of 851
companies
in the Medical Devices & Instruments industry
Industry Median: 0.64
vs TSXV:ZCT: 0.41
Zero Candida Technologies (TSXV:ZCT) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Zero Candida Technologies Equity-to-Asset Related Terms
Zero Candida Technologies Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSXV:ZCT vs ABT, SYK, MDT: Equity-to-Asset Comparison
For the Medical Devices subindustry, Zero Candida Technologies's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zero Candida Technologies Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Zero Candida Technologies's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Zero Candida Technologies's Equity-to-Asset falls into.
Zero Candida Technologies Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Zero Candida Technologies's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zero Candida Technologies (TSXV:ZCT) has a Equity-to-Asset of 0.41 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Zero Candida Technologies and its competitors. This is near median its historical median of 0.41. According to the industry distribution chart, Zero Candida Technologies ranks #642 out of 851 companies in the Medical Devices & Instruments industry, placing it in the top 75.4%.
Is Zero Candida Technologies' Equity-to-Asset too high?
Zero Candida Technologies' current Equity-to-Asset of 0.41 is near median its 10-year median of 0.41. The Medical Devices & Instruments industry median Equity-to-Asset is 0.64. Zero Candida Technologies' value of 0.41 is 35.9% below this industry median. Based on the distribution chart, Zero Candida Technologies ranks #642 out of 851 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Zero Candida Technologies has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Zero Candida Technologies' Equity-to-Asset compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Zero Candida Technologies ranks #642 out of 851 companies for Equity-to-Asset. This places Zero Candida Technologies in the lower half of its industry. The industry median Equity-to-Asset is 0.64. Zero Candida Technologies' value of 0.41 is 35.9% below this benchmark. While the company's 10-year median is 0.41 vs. the industry median of 0.64, Zero Candida Technologies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.64, based on 851 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zero Candida Technologies's current Equity-to-Asset of 0.41 is 35.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Zero Candida Technologies and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zero Candida Technologies's current Equity-to-Asset is 0.41, which is near median its own 10-year median of 0.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zero Candida Technologies stock overvalued right now?
Zero Candida Technologies (TSXV:ZCT) has a current Equity-to-Asset of 0.41. The current Equity-to-Asset is 0.41, which is near median its 10-year median of 0.41 and 35.9% below the Medical Devices & Instruments industry median of 0.64. Zero Candida Technologies' overall GF Score™ is 15/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Zero Candida Technologies (TSXV:ZCT), the current Equity-to-Asset is 0.41 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Zero Candida Technologies Inc is engaged in providing female healthcare solutions. The company technology uses a controlled Blue Light to destroy the fungus at record speed and without side effects. It focused on developing and commercializing several patents and patent applications concerning an AI smart tampon-like device, designed to treat Candidiasis and transfer medical information via Wi-Fi to the doctor.
15GF Score
Get the complete analysis for TSXV:ZCT
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:ZCT has been successfully added to your 
